{
  "id": "6027549d1cb411341a0000ea",
  "type": "list",
  "question": "Which drugs are included in the CAPIRI regimen?",
  "ideal_answer": "CAPIRI regimen includes capecitabine plus irinotecan.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25534239",
    "http://www.ncbi.nlm.nih.gov/pubmed/33270098",
    "http://www.ncbi.nlm.nih.gov/pubmed/21300933",
    "http://www.ncbi.nlm.nih.gov/pubmed/19152449",
    "http://www.ncbi.nlm.nih.gov/pubmed/19526201",
    "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
    "http://www.ncbi.nlm.nih.gov/pubmed/19713248",
    "http://www.ncbi.nlm.nih.gov/pubmed/31144145",
    "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
    "http://www.ncbi.nlm.nih.gov/pubmed/27121793",
    "http://www.ncbi.nlm.nih.gov/pubmed/32703200",
    "http://www.ncbi.nlm.nih.gov/pubmed/25889149",
    "http://www.ncbi.nlm.nih.gov/pubmed/30049885",
    "http://www.ncbi.nlm.nih.gov/pubmed/15684318",
    "http://www.ncbi.nlm.nih.gov/pubmed/22240792",
    "http://www.ncbi.nlm.nih.gov/pubmed/28968978",
    "http://www.ncbi.nlm.nih.gov/pubmed/17325705"
  ],
  "snippets": [
    {
      "text": "AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600\u2009mg/m2), irinotecan (IRI: 200\u2009mg/m2), and BEV (7.5\u2009mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objective: To compare the efficacy of capecitabine plus irinotecan (CAPIRI) vs irinotecan (IRI) alone in patients with advanced gallbladder cancer (GBC) who have disease progression after gemcitabine-based first-line treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33270098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31144145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The aim of this randomized, multicenter, noncomparative, phase II trial was to investigate the efficacy and safety of two potential first-line treatments, capecitabine and oxaliplatin (CapOX) plus bevacizumab (BEV) and capecitabine and irinotecan (CapIRI) plus bevacizumab, in Japanese patients with metastatic colorectal cancer (mCRC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30049885",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A large series of samples (n=818) from two phase III clinical trials was used to evaluate these candidate genes by correlating methylation status to progression-free survival after treatment with first-line single-agent fluorouracil (Capecitabine or 5-fluorouracil) or combination chemotherapy (Capecitabine or 5-fluorouracil plus irinotecan (CAPIRI/FOLFIRI)).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among these patients, 90 received capecitabine monotherapy as first-line therapy, and 93 received capecitabine plus irinotecan (CAPIRI) therapy as part of the CAIRO phase III clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121793",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534239",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regimen every 3 wk. D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19152449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22240792",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300933",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31144145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e capecitabine has been effectively and safely combined with irinotecan (CAPIRI) and/or oxaliplatin (CAPOX). Three randomized phase I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19713248",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: To establish the feasibility and efficacy of capecitabine in combination with weekly irinotecan (CAPIRI) with concurrent pelvic radiotherapy (RT) in patients with locally advanced rectal c",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15684318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer. Pati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined. We id",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534239",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25889149",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17325705",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17325705",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ient clinics. Patients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regim",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19152449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: To establish the feasibility and efficacy of capecitabine in combination with weekly irinotecan (CAPIRI) with concurrent pelvic radiotherapy (RT) in patients with locally advanced rectal cancer.PATIENTS AND METHODS: Nineteen patients with rectal cancer clinical stage T3-4, Nx received weekly irinotecan 50 mg/m(2) (days 1, 8, 15, 22, 29) and two doses of capecitabine (days 1 through 38; dose level [DL] I, 500 mg/m(2) bid; DL II, 625 mg/m(2) bid) ac",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15684318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC).PATIENTS AND METHODS: A total of 185 patients with mCRC were randomly assigned to cetuximab (400 mg/m(2) day 1, followed by 250 mg/m(2) weekly) plus CAPIRI (irinotecan 200 mg/m(2), day 1; capecitabine 800 mg/m(2) twice daily days 1 through 14, every 3 weeks; or cetuximab plus CAPOX (oxaliplatin 130 mg/m(2) day 1; capecitabine 1,000 mg/m(2) twice daily da",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300933",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19526201",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The oral fluoropyrimidine capecitabine has been effectively and safely combined with irinotecan (CAPIRI) and/or oxaliplatin (CAPOX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "capecitabine, irinotecan"
}